Developer docs
API playgroundTry for free, no card

Search company profiles

Kibow Biotech

Full company profile

uuid000dr6a

Namestring
Kibow Biotech
Legal namestring
Kibow Biotech LLC
Company typeenum
Private
Founded yearint
1997
Descriptiontext

Kibow Biotech is a privately held biotechnology company founded in 1997 by Dr. Natarajan Ranganathan and headquartered in Exton, Pennsylvania. It develops science-based probiotics and prebiotics targeting the gut-kidney axis to support kidney health, with its proprietary platform branded as Enteric Dialysis™. The company serves primarily chronic kidney disease (CKD) and end-stage renal disease (ESRD) patients, at-risk individuals, and healthcare providers (particularly nephrologists) who recommend its products as adjuncts to conventional kidney care.

The core product line is Renadyl®, a patented probiotic supplement delivering 45 billion CFUs per acid-resistant capsule of three proprietary strains—Streptococcus thermophilus KB19, Lactobacillus acidophilus, and Bifidobacterium longum—that metabolize nitrogenous waste compounds (urea, uric acid, creatinine) in the gastrointestinal tract. The portfolio also includes Renadyl® Advanced Multivitamin, a phosphorus- and potassium-free gummy multivitamin launched in November 2025 for CKD/ESRD patients, and Kibow Fortis®, a six-fiber prebiotic supplement supporting digestive and immune health. A separate clinical-stage entity, Kibow Pharmaceuticals LLC, is advancing US-APR2020, a live biotherapeutic product in a Phase IIb global trial for CKD Stage IV following FDA IND approval in April 2021. The technology base is supported by 20+ years of peer-reviewed clinical research, U.S. and India patents, and trademarks for Renadyl®, Enteric Dialysis™, and Kibow Fortis®.

Kibow operates a hybrid go-to-market combining direct-to-consumer e-commerce through shop.kibow.com (offering 90-day supply bundles with free U.S. shipping) with a network of country-exclusive distribution partners across the United States, Canada, the Philippines, Romania, South Korea, Poland, Singapore, India, and Argentina. Revenue is generated through one-time unit-priced supplement sales. The company is founder-controlled, with research historically supported by NIH SBIR grants rather than institutional equity capital, and operates with 11–50 employees.

Short descriptiontext

Kibow Biotech is a privately held Pennsylvania-based biotechnology company that develops clinically studied probiotic and prebiotic supplements—led by Renadyl®—targeting the gut-kidney axis to support chronic kidney disease patients worldwide through DTC e-commerce and country-exclusive distributors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNewtown Square, United States
HQ citystring
Newtown Square
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
kidney health probiotics, gut-kidney axis supplements, nephrology dietary supplements, probiotic formulations, enteric dialysis technology
Industry3 codes
PRIMARYHLAAAFAA
Live Biotherapeutic Products (LBPs)
SECONDARYCRADAGAF
Probiotics & Digestive Health Supplements
SECONDARYAFAJAKAE
Probiotics (Strains, Spore-Formers, Synbiotic Components)
Agriculture & Food Production/Food Ingredients & Additives/Nutraceutical & Functional Ingredients (Vitamins, Minerals, Omega-3s, Botanicals)
NAICS code1 code
  • Food (Health) Supplement Retailers456191
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Probiotic Kidney Health Supplements
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Probiotic Dietary Supplements Sales
TypeOne Time License
Description

Kibow Biotech generates revenue through the sale of its probiotic dietary supplement products including Renadyl® (kidney health probiotic), Renadyl® Advanced Multivitamin (kidney-specific gummy multivitamin), and Kibow Fortis® (prebiotic multifiber). Products are sold directly to consumers and through distribution partners globally.

kibowbiotech.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels8 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations
Pricing details1 tier
1Renadyl® Kidney Health Supplement 90-Day Supply
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Free shipping in USA with 3-month supply purchase

kibowbiotech.com
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1Renadyl
Description

The #1 nephrologist-recommended probiotic dietary supplement clinically proven to improve or maintain kidney function. Contains 45 billion CFUs of three proprietary probiotic strains.

kibowbiotech.com
+4 more records
Core offering1 text field

Kibow Biotech develops, manufactures, and sells clinically-formulated probiotic and prebiotic dietary supplements that target the gut-kidney axis to support kidney function in patients with Chronic Kidney Disease (CKD) and End-Stage Renal Disease (ESRD). The portfolio centers on Renadyl®, a patented probiotic supplement delivering 45 billion CFUs of proprietary bacterial strains that metabolize nitrogenous waste (urea, uric acid, creatinine) in the gastrointestinal tract, complemented by Renadyl® Advanced Multivitamin (kidney-specific gummy) and Kibow Fortis® (prebiotic multifiber).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 45 billion CFUs per capsule
+4 more records
Product overview1 text field

Kibow Biotech offers a portfolio of scientifically-formulated probiotic and prebiotic solutions targeting the gut-kidney axis to support kidney health. The core product is Renadyl®, a patented probiotic supplement containing 45 billion CFUs of three proprietary strains that metabolize nitrogenous toxins. This is complemented by Renadyl® Advanced Multivitamin (the first gummy multivitamin for kidney health patients, avoiding phosphorus and potassium) and Kibow Fortis®, a multi-fiber prebiotic supplement designed to support digestive and immune health. All products work together to address different aspects of kidney health and overall wellness through microbiome modulation.

Product and service3 records
1Renadyl® Probiotic Kidney Health Supplement
CategoryProbiotic Kidney Health Supplement
Description

Patented probiotic health supplement clinically proven to improve or maintain kidney function. Each acid-resistant capsule delivers 45 billion CFUs of three proprietary strains (Streptococcus thermophilus KB19, Lactobacillus acidophilus, Bifidobacterium longum) that metabolize nitrogenous toxins such as urea, uric acid, and creatinine within the gastrointestinal tract. Positioned as the #1 nephrologist-recommended probiotic dietary kidney supplement, intended for CKD and ESRD patients.

2Renadyl® Advanced Multivitamin
CategoryKidney-Specific Multivitamin
Description

First and only gummy multivitamin specially formulated for people managing CKD or ESRD. Complements Renadyl probiotic therapy by providing targeted nutritional support while avoiding phosphorus and potassium, which are restricted in kidney patients' diets.

3Kibow Fortis® Prebiotic Multifiber
CategoryPrebiotic Dietary Supplement
Description

Scientifically formulated prebiotic multi-fiber dietary supplement designed to support digestive health and intestinal flora balance. Contains six prebiotic fibers to nourish beneficial gut bacteria while supporting satiety, lipid balance, and immune health for kidney patients and the broader at-risk population.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
1Kibow Pharmaceuticals LLC
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-07-24
Description

Phase 2/3 clinical-stage company focused on developing novel live biotherapeutic products (LBP) for CKD patients. First clinical product US-APR2020 is in Phase IIb multi-site global clinical trial recruiting CKD stage 4 subjects.

kibowbiotech.com
2Centaur Pharmaceuticals
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2018-03-08
Description

Strategic alliance announced on World Kidney Day 2018 to market Renadyl in India. Given the high prevalence of Chronic Kidney Illness in India (17.2% and rising), this partnership addresses a significant market opportunity for Kibow's patented and clinically-tested kidney health supplement.

kibowbiotech.com
3Dega International Pharma Corp.
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Exclusive distributor for Renadyl in the Philippines (PHL), enabling access to the Southeast Asian market for Kibow's kidney health products.

kibowbiotech.com
4Gelda Scientific
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Canadian distributor for Kibow products, providing access to the Canadian market for Renadyl and other kidney health supplements.

kibowbiotech.com
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Romanian distributor for Renadyl and Kibow product line, enabling market access in Eastern Europe.

6Tailored Probio
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

South Korean distribution partner for Kibow's probiotic supplements, expanding presence in the Asian market.

kibowbiotech.com
7Rebonum
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Polish distributor for Kibow products, enabling access to the European market.

kibowbiotech.com
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Singapore-based distributor for Kibow's kidney health products, providing market access in Singapore.

Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Academic research partner for open-label dose escalation study of Kibow Biotics (Renadyl) in CKD Stage III and IV patients, conducted May 2011 to December 2012.

Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Academic partner for double-blind, randomized, placebo-controlled crossover study in CKD patients on dialysis (Renadyl), conducted April 2011 to December 2012. Led by Dr. Eli A. Friedman.

Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Research collaboration for in vitro studies using Simulated Human Intestinal Microbial Ecosystem (SHIME) biochemical reactor to study probiotic formulations for uremia therapy.

Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Collaboration for preclinical studies in 5/6th nephrectomized minipig models of chronic renal failure, studying probiotic bacteriotherapy applications.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1BioGaia
TypeDirect peer
Description

Swedish probiotics company developing clinically documented probiotic strains for specific health conditions, with a similar model of pairing proprietary strains with health-condition-specific branding. Most comparable as a clinically-oriented probiotic supplement company with B2B and B2C channels.

2Culturelle (i-Health / Chr. Hansen)
TypeDirect peer
Description

One of the largest clinically-backed probiotic supplement brands in the US, sold through mass retail and pharmacy channels. Competes with Kibow in the digestive/gut-health probiotic shelf space and shares the clinical-credibility positioning model.

TypeDirect peer
Description

Premium DTC probiotic brand built on proprietary strain science and published clinical research. Comparable to Kibow's premium clinical-credibility positioning and direct-to-consumer e-commerce distribution model.

TypeEmerging player
Description

Microbiome company developing probiotic and prebiotic products targeting metabolic conditions, with a clinical evidence-driven DTC model. Comparable to Kibow as a science-forward microbiome company targeting chronic disease consumers.

5Ganeden (Kerry Group)
TypeDirect peer
Description

Probiotic ingredient technology company (GanedenBC30 / Bacillus coagulans GBI-30) that licenses proprietary strains into supplements and functional foods. Comparable to Kibow's proprietary-strain licensing and B2B ingredient strategy.

TypeBroad incumbent
Description

Global probiotic dairy beverage company built around the proprietary Lactobacillus casei Shirota strain with decades of clinical research. Comparable as a scaled, science-led probiotic brand targeting gut health consumers globally.

TypeBroad incumbent
Description

Multinational food giant with the largest probiotic food and beverage portfolio globally. Comparable to Kibow as a scaled probiotic brand operator, though far broader in scope and distribution.

TypeBroad incumbent
Description

Global bioscience company producing probiotic cultures, enzymes, and microbial solutions for supplements, dairy, and infant nutrition. Comparable to Kibow on the probiotic strain science and ingredient side of the business.

TypeEmerging player
Description

Late-stage biopharmaceutical company developing therapies for kidney disease (e.g., tenapanor for hyperphosphatemia in CKD). Comparable to Kibow as a CKD-focused therapeutics company targeting nitrogenous waste management.

TypeBroad incumbent
Description

Multinational pharmaceutical company whose drug Farxiga (dapagliflozin) is approved for CKD. Comparable to Kibow as a player addressing the CKD market, though at scale and as a guideline-directed prescription therapy rather than an adjunct supplement.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kibow Biotech

Probiotic Kidney Health Supplementskibowbiotech.com

Kibow Biotech is a privately held Pennsylvania-based biotechnology company that develops clinically studied probiotic and prebiotic supplements—led by Renadyl®—targeting the gut-kidney axis to support chronic kidney disease patients worldwide through DTC e-commerce and country-exclusive distributors.

What Kibow Biotech does

Kibow Biotech is a privately held biotechnology company founded in 1997 by Dr. Natarajan Ranganathan and headquartered in Exton, Pennsylvania. It develops science-based probiotics and prebiotics targeting the gut-kidney axis to support kidney health, with its proprietary platform branded as Enteric Dialysis™. The company serves primarily chronic kidney disease (CKD) and end-stage renal disease (ESRD) patients, at-risk individuals, and healthcare providers (particularly nephrologists) who recommend its products as adjuncts to conventional kidney care.

The core product line is Renadyl®, a patented probiotic supplement delivering 45 billion CFUs per acid-resistant capsule of three proprietary strains—Streptococcus thermophilus KB19, Lactobacillus acidophilus, and Bifidobacterium longum—that metabolize nitrogenous waste compounds (urea, uric acid, creatinine) in the gastrointestinal tract. The portfolio also includes Renadyl® Advanced Multivitamin, a phosphorus- and potassium-free gummy multivitamin launched in November 2025 for CKD/ESRD patients, and Kibow Fortis®, a six-fiber prebiotic supplement supporting digestive and immune health. A separate clinical-stage entity, Kibow Pharmaceuticals LLC, is advancing US-APR2020, a live biotherapeutic product in a Phase IIb global trial for CKD Stage IV following FDA IND approval in April 2021. The technology base is supported by 20+ years of peer-reviewed clinical research, U.S. and India patents, and trademarks for Renadyl®, Enteric Dialysis™, and Kibow Fortis®.

Kibow operates a hybrid go-to-market combining direct-to-consumer e-commerce through shop.kibow.com (offering 90-day supply bundles with free U.S. shipping) with a network of country-exclusive distribution partners across the United States, Canada, the Philippines, Romania, South Korea, Poland, Singapore, India, and Argentina. Revenue is generated through one-time unit-priced supplement sales. The company is founder-controlled, with research historically supported by NIH SBIR grants rather than institutional equity capital, and operates with 11–50 employees.

Kibow Biotech firmographics

Firmographics
Name
Kibow Biotech
Legal name
Kibow Biotech LLC
Website
https://kibowbiotech.com
Company type
Private
Founded year
1997
Operating status
Operating
Headcount range
11–50 employees
Short description
Kibow Biotech is a privately held Pennsylvania-based biotechnology company that develops clinically studied probiotic and prebiotic supplements—led by Renadyl®—targeting the gut-kidney axis to support chronic kidney disease patients worldwide through DTC e-commerce and country-exclusive distributors.
Ownership category
akta.pro rank

Kibow Biotech industry classification

Industry
Product category
Probiotic Kidney Health Supplements
NAICS
Food (Health) Supplement Retailers (456191)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAFAA
Live Biotherapeutic Products (LBPs)
SECONDARYCRADAGAF
Probiotics & Digestive Health Supplements
SECONDARYAFAJAKAE
Probiotics (Strains, Spore-Formers, Synbiotic Components)
Agriculture & Food Production/Food Ingredients & Additives/Nutraceutical & Functional Ingredients (Vitamins, Minerals, Omega-3s, Botanicals)

Keywords

  • Kidney health probiotics
  • Gut-kidney axis supplements
  • Nephrology dietary supplements
  • Probiotic formulations
  • Enteric dialysis technology

Where Kibow Biotech is headquartered

Location

Headquarters

HQ city
Newtown Square
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Kibow Biotech business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

  1. Probiotic Dietary Supplements Sales: Kibow Biotech generates revenue through the sale of its probiotic dietary supplement products including Renadyl® (kidney health probiotic), Renadyl® Advanced Multivitamin (kidney-specific gummy multivitamin), and Kibow Fortis® (prebiotic multifiber). Products are sold directly to consumers and through distribution partners globally.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goRenadyl® Kidney Health Supplement 90-Day Supply

Go-to-market motion2 records

Distribution channels8 records

Marketing channels6 records

Kibow Biotech product offering

Product offering

Core offering

Kibow Biotech develops, manufactures, and sells clinically-formulated probiotic and prebiotic dietary supplements that target the gut-kidney axis to support kidney function in patients with Chronic Kidney Disease (CKD) and End-Stage Renal Disease (ESRD). The portfolio centers on Renadyl®, a patented probiotic supplement delivering 45 billion CFUs of proprietary bacterial strains that metabolize nitrogenous waste (urea, uric acid, creatinine) in the gastrointestinal tract, complemented by Renadyl® Advanced Multivitamin (kidney-specific gummy) and Kibow Fortis® (prebiotic multifiber).

Product overview

Kibow Biotech offers a portfolio of scientifically-formulated probiotic and prebiotic solutions targeting the gut-kidney axis to support kidney health. The core product is Renadyl®, a patented probiotic supplement containing 45 billion CFUs of three proprietary strains that metabolize nitrogenous toxins. This is complemented by Renadyl® Advanced Multivitamin (the first gummy multivitamin for kidney health patients, avoiding phosphorus and potassium) and Kibow Fortis®, a multi-fiber prebiotic supplement designed to support digestive and immune health. All products work together to address different aspects of kidney health and overall wellness through microbiome modulation.

Differentiator

Problem solved

Functional benefit

Brands

  • Renadyl: The #1 nephrologist-recommended probiotic dietary supplement clinically proven to improve or maintain kidney function. Contains 45 billion CFUs of three proprietary probiotic strains.
  • Renadyl Advanced Multivitamin
  • Kibow Fortis
  • US-APR2020
  • Enteric Dialysis

Products and services

  • Renadyl® Probiotic Kidney Health Supplement Patented probiotic health supplement clinically proven to improve or maintain kidney function. Each acid-resistant capsule delivers 45 billion CFUs of three proprietary strains (Streptococcus thermophilus KB19, Lactobacillus acidophilus, Bifidobacterium longum) that metabolize nitrogenous toxins such as urea, uric acid, and creatinine within the gastrointestinal tract. Positioned as the #1 nephrologist-recommended probiotic dietary kidney supplement, intended for CKD and ESRD patients.
  • Renadyl® Advanced Multivitamin First and only gummy multivitamin specially formulated for people managing CKD or ESRD. Complements Renadyl probiotic therapy by providing targeted nutritional support while avoiding phosphorus and potassium, which are restricted in kidney patients' diets.
  • Kibow Fortis® Prebiotic Multifiber Scientifically formulated prebiotic multi-fiber dietary supplement designed to support digestive health and intestinal flora balance. Contains six prebiotic fibers to nourish beneficial gut bacteria while supporting satiety, lipid balance, and immune health for kidney patients and the broader at-risk population.

Quantifiable outcome

  • 45 billion CFUs per capsule
  • +4 more outcomes

Companies that use Kibow Biotech

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Kibow Biotech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Kibow Biotech partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered core and strategic.

  • Kibow Pharmaceuticals LLCcoreStrategic or Co-development Partner · 24 July 2019Phase 2/3 clinical-stage company focused on developing novel live biotherapeutic products (LBP) for CKD patients. First clinical product US-APR2020 is in Phase IIb multi-site global clinical trial recruiting CKD stage 4 subjects.
  • Centaur PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 8 March 2018Strategic alliance announced on World Kidney Day 2018 to market Renadyl in India. Given the high prevalence of Chronic Kidney Illness in India (17.2% and rising), this partnership addresses a significant market opportunity for Kibow's patented and clinically-tested kidney health supplement.
  • Dega International Pharma Corp.coreChannel Partner/ Reseller/ DistributorExclusive distributor for Renadyl in the Philippines (PHL), enabling access to the Southeast Asian market for Kibow's kidney health products.
  • Gelda ScientificcoreChannel Partner/ Reseller/ DistributorCanadian distributor for Kibow products, providing access to the Canadian market for Renadyl and other kidney health supplements.
  • Healthy Medical SRLcoreChannel Partner/ Reseller/ DistributorRomanian distributor for Renadyl and Kibow product line, enabling market access in Eastern Europe.
  • Tailored ProbiocoreChannel Partner/ Reseller/ DistributorSouth Korean distribution partner for Kibow's probiotic supplements, expanding presence in the Asian market.
  • RebonumcoreChannel Partner/ Reseller/ DistributorPolish distributor for Kibow products, enabling access to the European market.
  • Z-Wave Lifestyle Pte Ltd.coreChannel Partner/ Reseller/ DistributorSingapore-based distributor for Kibow's kidney health products, providing market access in Singapore.
  • Thomas Jefferson UniversitystrategicStrategic or Co-development PartnerAcademic research partner for open-label dose escalation study of Kibow Biotics (Renadyl) in CKD Stage III and IV patients, conducted May 2011 to December 2012.
  • SUNY-Downstate Medical CenterstrategicStrategic or Co-development PartnerAcademic partner for double-blind, randomized, placebo-controlled crossover study in CKD patients on dialysis (Renadyl), conducted April 2011 to December 2012. Led by Dr. Eli A. Friedman.
  • Ghent University (Belgium)strategicStrategic or Co-development PartnerResearch collaboration for in vitro studies using Simulated Human Intestinal Microbial Ecosystem (SHIME) biochemical reactor to study probiotic formulations for uremia therapy.
  • Indiana University School of MedicinestrategicStrategic or Co-development PartnerCollaboration for preclinical studies in 5/6th nephrectomized minipig models of chronic renal failure, studying probiotic bacteriotherapy applications.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Kibow Biotech competitors and assessment

Company assessment

Direct peers

  • BioGaia: Swedish probiotics company developing clinically documented probiotic strains for specific health conditions, with a similar model of pairing proprietary strains with health-condition-specific branding. Most comparable as a clinically-oriented probiotic supplement company with B2B and B2C channels.
  • Culturelle (i-Health / Chr. Hansen): One of the largest clinically-backed probiotic supplement brands in the US, sold through mass retail and pharmacy channels. Competes with Kibow in the digestive/gut-health probiotic shelf space and shares the clinical-credibility positioning model.
  • Seed Health: Premium DTC probiotic brand built on proprietary strain science and published clinical research. Comparable to Kibow's premium clinical-credibility positioning and direct-to-consumer e-commerce distribution model.
  • Ganeden (Kerry Group): Probiotic ingredient technology company (GanedenBC30 / Bacillus coagulans GBI-30) that licenses proprietary strains into supplements and functional foods. Comparable to Kibow's proprietary-strain licensing and B2B ingredient strategy.

Emerging players

  • Pendulum Therapeutics: Microbiome company developing probiotic and prebiotic products targeting metabolic conditions, with a clinical evidence-driven DTC model. Comparable to Kibow as a science-forward microbiome company targeting chronic disease consumers.
  • Ardelyx: Late-stage biopharmaceutical company developing therapies for kidney disease (e.g., tenapanor for hyperphosphatemia in CKD). Comparable to Kibow as a CKD-focused therapeutics company targeting nitrogenous waste management.

Broad incumbents

  • Yakult Honsha: Global probiotic dairy beverage company built around the proprietary Lactobacillus casei Shirota strain with decades of clinical research. Comparable as a scaled, science-led probiotic brand targeting gut health consumers globally.
  • Danone (Activia / Actimel): Multinational food giant with the largest probiotic food and beverage portfolio globally. Comparable to Kibow as a scaled probiotic brand operator, though far broader in scope and distribution.
  • Chr. Hansen: Global bioscience company producing probiotic cultures, enzymes, and microbial solutions for supplements, dairy, and infant nutrition. Comparable to Kibow on the probiotic strain science and ingredient side of the business.
  • AstraZeneca: Multinational pharmaceutical company whose drug Farxiga (dapagliflozin) is approved for CKD. Comparable to Kibow as a player addressing the CKD market, though at scale and as a guideline-directed prescription therapy rather than an adjunct supplement.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Kibow Biotech social profiles

Digital presence

Kibow Biotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kibow Biotech leadership team

Management profile

Number of profiles

Profiles1 record

Kibow Biotech funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kibow Biotech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kibow Biotech

What does Kibow Biotech do?

Kibow Biotech develops, manufactures, and sells clinically-formulated probiotic and prebiotic dietary supplements that target the gut-kidney axis to support kidney function in patients with Chronic Kidney Disease (CKD) and End-Stage Renal Disease (ESRD). The portfolio centers on Renadyl®, a patented probiotic supplement delivering 45 billion CFUs of proprietary bacterial strains that metabolize nitrogenous waste (urea, uric acid, creatinine) in the gastrointestinal tract, complemented by Renadyl® Advanced Multivitamin (kidney-specific gummy) and Kibow Fortis® (prebiotic multifiber).

Is Kibow Biotech a public or private company?

Kibow Biotech is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Kibow Biotech founded?

Kibow Biotech was founded in 1997. It employs 11 to 50 people.

Where is Kibow Biotech based?

Kibow Biotech is headquartered in Newtown Square, United States, in the North America region.

How does Kibow Biotech make money?

One revenue line is on record: probiotic Dietary Supplements Sales.

Who are Kibow Biotech's main competitors?

Direct peers on record are BioGaia, Culturelle (i-Health / Chr. Hansen), Seed Health and Ganeden (Kerry Group). Emerging players are Pendulum Therapeutics and Ardelyx. Broad incumbents are Yakult Honsha, Danone (Activia / Actimel), Chr. Hansen and AstraZeneca.

Does Kibow Biotech have an API?

No public API is recorded for Kibow Biotech.

What industry is Kibow Biotech in?

Kibow Biotech's product category is Probiotic Kidney Health Supplements. Its primary akta.pro industry code is HLAAAFAA, Live Biotherapeutic Products (LBPs), with a secondary code of CRADAGAF, Probiotics & Digestive Health Supplements. Its NAICS code is 456191 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
LelezardKibow® Biotech annonce la commercialisation de Renadyl® au CanadaKibow Biotech announced the launch of Renadyl in Canada, a probiotic supplement containing 45 billion colony-forming units with delayed-release technology. The product is available on Renadyl.ca, and the company stated it aims to make its probiotic formulations accessible to more consumers worldwide.NewswireKibow® Biotech Announces Availability of Renadyl® in CanadaKibow Biotech announced Renadyl is now available in Canada, a probiotic supplement with 45 billion CFUs and delayed-release technology. The product targets gut microbiome balance and is sold at Renadyl.ca. The launch reflects the company's international expansion.PR NewswireKibow® Biotech Announces Availability of Renadyl® in CanadaKibow Biotech announced Renadyl, a probiotic supplement for kidney health, is now available in Canada. The product delivers 45 billion CFUs per serving and targets gut-based management of waste compounds. It is sold at Renadyl.ca.PR NewswireKibow Therapeutics to Present Phase 2b Results for KT-301 in Stage 4 Chronic Kidney Disease at ASN Kidney Week 2026Kibow Therapeutics will present Phase 2b results for KT-301 in Stage 4 CKD at ASN Kidney Week 2026, with data from 327 patients. The company also plans a poster on KT-301's mechanism of action. The presentations occur on October 23 in Denver.PR NewswireKibow® Biotech Wins 2026 WebAward for Best Science WebsiteKibow Biotech's redesigned website won Best Science Website in the 2026 WebAward Competition. The company, founded in 1997, has expanded its kidney health products globally, including Renadyl and upcoming Renaphil for pets. The award highlights its commitment to advancing gut-kidney axis research.MorningstarKibow® Biotech Wins 2026 WebAward for Best Science WebsiteKibow Biotech's newly redesigned website won Best Science Website in the 2026 WebAward Competition. The company, founded in 1997, is expanding its kidney health solutions, including upcoming launches of Renaphil for pets and expansion into Canada.PR NewswireKibow® Biotech Honored with The American Association of Naturopathic Physicians Corporation of the Year AwardKibow Biotech has been named the recipient of the American Association of Naturopathic Physicians (AANP) Corporation of the Year Award at their annual Membership Meeting. The award recognizes the company's 25+ years of commitment to advancing naturopathic medicine through scientific research, practitioner support, and development of probiotic dietary supplements like Renadyl® designed to support kidney health via the gut-kidney axis.PR NewswireKibow Biotech Celebrates Its 24th Anniversary with a Continued Mission to Support the 2019 Washington, DC Declaration of "Decade of the Kidney™." It Proposes Several Clinical Trials on CKD-IV, DialysiKibow Biotech Inc, a clinical-stage biotechnology company founded in Philadelphia in 1997, is celebrating its 24th anniversary and providing an update on its pipeline of probiotic dietary supplements and live biotherapeutic products for chronic kidney disease. The company, through its subsidiary Kibow Pharmaceutical LLC, has commenced a US FDA-approved Phase 2(b) clinical trial evaluating its investigational live biotherapeutic product (US-APR 2020) in 630 subjects with CKD-IV at approximately 20 US clinical sites, with seven sites already screening and enrolling subjects as of September 2021. Kibow is seeking $25 million in Series A growth capital for its pharmaceutical division and has active licensing agreements for its kidney health supplements with Centaur Pharmaceuticals in India and Vetoquinol in France.PR NewswireKibow Biotech Announces FDA Approval of IND to Initiate Phase II Clinical Trial of US-APR2020 to Treat Chronic Kidney Disease Stage IVKibow Biotech announced FDA approval of its Investigational New Drug (IND) application for US-APR2020 to treat Chronic Kidney Disease stage IV patients, marking the company's transition from a dietary supplement company to a Phase II clinical-stage biopharmaceutical. The randomized, double-blind, placebo-controlled trial will evaluate the probiotic formulation's ability to arrest estimated Glomerular Filtration Rate decline by 40% from baseline over six months, with enrollment anticipated to begin in Q3 2021. The company has launched Kibow Pharmaceuticals as a separate wholly-owned subsidiary to advance the live biotherapeutic product under CBER and FDA regulations.PR NewswireKibow Biotech Supports World Kidney Day 2021Kibow Biotech announced its support for World Kidney Day 2021 on March 11, 2021, with a social media campaign to raise awareness about kidney health and the transplant shortage. The company, which has 23 years of R&D experience with its probiotic supplement Renadyl™, has launched a new pharmaceutical division to transition the product into a Live Biotherapeutic Product under FDA regulations, initiating the Investigational New Drug submission process and planning clinical trials. Kibow aims to participate in the KidneyX program competition and believes the transition could reduce US dialysis costs by billions while improving patient quality of life.